Hepatocellular Carcinoma


Aflatoxin or chronic infection with hepatitis B and C virus is the predominant risk factor for HCC in Southeast Asia and Africa, while chronic infection with hepatitis C virus and hepatic cirrhosis (mostly alcoholism) are the predominant risk factors for HCC in Western countries and Japan.

Hepatocarcinogenesis is a complex process associated with accumulation of genetic and epigenetic changes that occur during initiation, promotion and progression of the disease. Some important cellular signaling pathways such as Wnt, P53, Jak/STAT, pRB, Ras/Raf Akt/ mTOR and growth factor are involved in HCC progression.

Systemic cytotoxic therapies have demonstrated a very limited impact on advancing HCC. Recently, the strategy of using specifi c inhibitors targeting tyrosine kinase and associated pathways has been tested in HCC clinical trials, such as Sorafenib, Bevacizumab and Sunitinib.

PharmaLegacy Models and Research Tools

Case Study -Inhibition of Tumor Growth